Literature DB >> 22182970

Ovarian cancer in 2011: Mutations and non-inferiority analyses show a way forward.

Maurie Markman1.   

Abstract

Highly clinically relevant ovarian cancer clinical research in 2011 focused on an increased understanding of the biology of the malignancy, limitations of strategies for early detection and screening, and the provocative reports of alternative primary and second-line management strategies.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22182970     DOI： 10.1038/nrclinonc.2011.200

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  7 in total

1.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

Authors:  Da Yang; Sofia Khan; Yan Sun; Kenneth Hess; Ilya Shmulevich; Anil K Sood; Wei Zhang
Journal:  JAMA       Date:  2011-10-12       Impact factor: 56.272

2.  "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.

Authors:  David S P Tan; Christian Rothermundt; Karen Thomas; Elizabeth Bancroft; Rosalind Eeles; Susan Shanley; Audrey Ardern-Jones; Andrew Norman; Stanley B Kaye; Martin E Gore
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

3.  Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Christina M Nagle; Jane E Francis; Anne E Nelson; Helen Zorbas; Karen Luxford; Anna de Fazio; Sian Fereday; David D Bowtell; Adèle C Green; Penelope M Webb
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

4.  Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.

Authors:  Sandro Pignata; Giovanni Scambia; Gabriella Ferrandina; Antonella Savarese; Roberto Sorio; Enrico Breda; Vittorio Gebbia; Pietro Musso; Luigi Frigerio; Pietro Del Medico; Alessandra Vernaglia Lombardi; Antonio Febbraro; Paolo Scollo; Antonella Ferro; Stefano Tamberi; Alba Brandes; Alberto Ravaioli; Maria Rosaria Valerio; Enrico Aitini; Donato Natale; Laura Scaltriti; Stefano Greggi; Carmela Pisano; Domenica Lorusso; Vanda Salutari; Francesco Legge; Massimo Di Maio; Alessandro Morabito; Ciro Gallo; Francesco Perrone
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

5.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

Authors:  Mary-Claire King; Joan H Marks; Jessica B Mandell
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

6.  Combining a symptoms index with CA 125 to improve detection of ovarian cancer.

Authors:  M Robyn Andersen; Barbara A Goff; Kimberly A Lowe; Nathalie Scholler; Lindsay Bergan; Charles W Dresher; Pamela Paley; Nicole Urban
Journal:  Cancer       Date:  2008-08-01       Impact factor: 6.860

7.  Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

Authors:  Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  JAMA       Date:  2011-06-08       Impact factor: 157.335
  7 in total
  2 in total

1.  Overexpression of TNKS1BP1 in lung cancers and its involvement in homologous recombination pathway of DNA double-strand breaks.

Authors:  Wei Tan; Hua Guan; Lian-Hong Zou; Yu Wang; Xiao-Dan Liu; Wei-Qing Rang; Ping-Kun Zhou; Hua-Dong Pei; Cai-Gao Zhong
Journal:  Cancer Med       Date:  2017-01-06       Impact factor: 4.452

2.  Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.

Authors:  Emily K Mader; Greg Butler; Sean C Dowdy; Andrea Mariani; Keith L Knutson; Mark J Federspiel; Stephen J Russell; Evanthia Galanis; Allan B Dietz; Kah-Whye Peng
Journal:  J Transl Med       Date:  2013-01-24       Impact factor: 5.531
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.